The Medical Letter on Drugs and Therapeutics
Sucroferric Oxyhydroxide (Velphoro) for Hyperphosphatemia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Sucroferric Oxyhydroxide (Velphoro) for Hyperphosphatemia
Most patients with end-stage renal disease develop hyperphosphatemia, which can lead to secondary hyperparathyroidism, vascular calcification, and cardiovascular mortality. The FDA has approved sucroferric oxyhydroxide (Velphoro – Fresenius...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Sucroferric Oxyhydroxide (Velphoro) for Hyperphosphatemia
Article code: 1449b
 Electronic, downloadable article - $45

Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.